Regentis Biomaterials
Regentis Biomaterials is a tissue repair company focused on developing and commercializing an innovative hydrogel platform for the repair of damaged tissue, especially in orthopedic treatments. Their lead product, GelrinC, is a cell-free, off-the-shelf hydrogel used for knee cartilage repair, aiming to offer effective, simple, and cost-efficient tissue regeneration therapies that improve patient recovery times and quality of life.
Industries
Nr. of Employees
small (1-50)
Regentis Biomaterials
60, Medinat Hyahudim, Entrance C, Herzlia Pituach, Israel 4676652
Patents
Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
US-9120872-B2
View DetailsScaffolds formed from polymer-protein conjugates, methods of generating same and uses thereof
US-8846020-B2
View DetailsMatrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
US-8007774-B2
View Details
Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
US-9120872-B2
View DetailsScaffolds formed from polymer-protein conjugates, methods of generating same and uses thereof
US-8846020-B2
View DetailsMatrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
US-8007774-B2
View DetailsProducts
GelrinC
Acellular, off‑the‑shelf biodegradable hydrogel implant for treatment of focal articular cartilage defects in the knee; applied as a liquid, cured in‑situ by UVA to form a conforming scaffold that degrades over months and is intended to be replaced by regenerated cartilage.
GelrinC
Acellular, off‑the‑shelf biodegradable hydrogel implant for treatment of focal articular cartilage defects in the knee; applied as a liquid, cured in‑situ by UVA to form a conforming scaffold that degrades over months and is intended to be replaced by regenerated cartilage.
Expertise Areas
- Regenerative medicine
- Orthopedic cartilage repair
- Hydrogel biomaterials development
- Clinical trial management for implantable devices
Key Technologies
- PEG‑based hydrogel biomaterials
- UV‑initiated in‑situ photopolymerization
- Surface‑erosion biodegradable scaffolds
- Acellular scaffold implant design
News & Updates
Regentis holds a portfolio of 34 issued patents and 3 pending applications, covering various aspects of their products, methods of manufacturing, delivery devices, and research programs.
Regentis holds a portfolio of 34 issued patents and 3 pending applications, covering various aspects of their products, methods of manufacturing, delivery devices, and research programs.